Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: efineptakin alfa Clear all
Completed Phase 1 Interventional

Safety Study of IL-7 in HIV-infected Patients (Inspire)

NCT00477321
View directory record Official record
Conditions
HIV Infections, Lymphopenia
Interventions
CYT 107
Drug
Lead sponsor
Cytheris SA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Miami, Florida • Bethesda, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Sep 5, 2026, 5:27 AM EDT
Terminated Phase 1 Interventional

A Trial of NT-I7 in COVID-19 (SPESELPIS)

NCT04501796
View directory record Official record
Conditions
COVID-19
Interventions
Double-Blind NT-I7, Double-Blind Placebo
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
19 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 5, 2026, 5:27 AM EDT
Completed Early Phase 1 Interventional

NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

NCT04781309
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
NT-I7
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 5, 2026, 5:27 AM EDT
Recruiting Phase 1 Interventional

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

NCT07052305
View directory record Official record
Conditions
Large B-cell Lymphoma
Interventions
NT-I7, CAR T-cell therapy
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 5, 2026, 5:27 AM EDT
Recruiting Phase 2 Interventional

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

NCT05465954
View directory record Official record
Conditions
High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Interventions
Biospecimen Collection, Efineptakin alfa, Pembrolizumab, Biopsy
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 5, 2026, 5:27 AM EDT
Withdrawn Phase 1 Interventional

Vaccine Response With NT-I7

NCT04054752
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
Interventions
Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 5, 2026, 5:27 AM EDT
Terminated Phase 1 Interventional

Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

NCT02659800
View directory record Official record
Conditions
Lymphopenia, Malignant Glioma
Interventions
Laboratory Biomarker Analysis, NT-I7, Placebo
Other · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 5, 2026, 5:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

NCT03687957
View directory record Official record
Conditions
Glioma
Interventions
rhIL-7-hyFc, Placebo, Temozolomide, Radiation therapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 5, 2026, 5:27 AM EDT
Terminated Phase 2 Interventional Results available

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

NCT04984811
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer
Interventions
efineptakin alfa, Atezolizumab
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Mobile, Alabama • Cerritos, California • Norwich, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 5, 2026, 5:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT04332653
View directory record Official record
Conditions
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer
Interventions
NT-I7, pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Tampa, Florida • Detroit, Michigan • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 5, 2026, 5:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

NCT05600920
View directory record Official record
Conditions
Idiopathic CD4 Lymphopenia
Interventions
Recombinant human interleukin (IL) 7-hyFc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 5, 2026, 5:27 AM EDT
Completed Phase 1 Interventional Results available

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

NCT05075603
View directory record Official record
Conditions
Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma, Primary Mediastinal Large B-cell Lymphoma
Interventions
Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel, Lisocabtagene Maraleucel
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Duarte, California • St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 5, 2026, 5:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

NCT00923351
View directory record Official record
Conditions
Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar, Neuroectodermal Tumors, Primitive, Peripheral
Interventions
Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7, Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Months to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 5, 2026, 5:27 AM EDT
Recruiting Phase 1 Interventional

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

NCT07200089
View directory record Official record
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
NT-I7, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 5, 2026, 5:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NCT03901573
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Interventions
NT-I7, atezolizumab
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 5, 2026, 5:27 AM EDT
Completed Phase 1 Interventional

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

NCT00684008
View directory record Official record
Conditions
AML, CML, MDS
Interventions
CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107)
Drug
Lead sponsor
Cytheris, Inc.
Industry
Eligibility
15 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Sep 5, 2026, 5:27 AM EDT
Terminated Phase 1 Interventional

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

NCT04588038
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Resectable Oropharyngeal Squamous Cell Carcinoma
Interventions
Efineptakin alfa
Biological
Lead sponsor
Hyunseok Kang, MD
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 5, 2026, 5:27 AM EDT
Terminated Phase 1 Interventional

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

NCT04594811
View directory record Official record
Conditions
Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)
Interventions
NT-I7, Nivolumab
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Louisville, Kentucky • Ann Arbor, Michigan • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Sep 5, 2026, 5:27 AM EDT
Terminated Phase 1 Interventional Results available

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

NCT04893018
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, HIV Infection, Kaposi Sarcoma
Interventions
Efineptakin alfa
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
San Francisco, California • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 5, 2026, 5:27 AM EDT